Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | TACR2 | P21452 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TST | Q16762 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29285307 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL177190 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL394553 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL395308 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| Hydrochloric Acid SCHEMBL1856278 | 0.98 | HTR2A (0.69) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL920406 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL29038707 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL393623 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL2674306 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 | |
| SCHEMBL4091747 | 0.98 | HTR2A (0.76) | HTR2AESR1ADRA2AADORA3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112624930-A | Preparation method of 2, 2-bis (4-aminophenyl) hexafluoropropane | 上海如鲲新材料有限公司 | 2021-04-09 | — | — | CN | claimed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | claimed |
| EP-4741405-A1 | ENHANCED PEROVSKITE MATERIALS FOR PHOTOVOLTAIC DEVICES | CubicPV Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3883940-B1 | ENHANCED PEROVSKITE MATERIALS FOR PHOTOVOLTAIC DEVICES | CUBICPV INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12540228-B2 | Cross linked surface coating and interfacial layer for a perovskite material photovoltaic device | CUBICPV INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12486235-B2 | Metal oxide nanoparticle with alkylsiloxane ligands bonded thereto | CUBICPV INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3883939-B1 | ENHANCED PEROVSKITE MATERIALS FOR PHOTOVOLTAIC DEVICES | CUBICPV INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12300485-B2 | Enhanced perovskite materials for photovoltaic devices | CubivPV Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12243740-B2 | Enhanced perovskite materials for photovoltaic devices | CUBICPV INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119136633-A | Enhanced perovskite materials for photovoltaic devices | 立方光伏股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| US-20030069127-A1 | Modified particle,support, catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMTED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1300425-A2 | Catalyst component for addition polymerization, process for producing said catalyst and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030060579-A1 | Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
| US-20020143124-A1 | Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1113026-A2 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
| CN-1069976-A | Hexanaphthene and tetrahydropyran derivatives | HOFFMANN LA ROCHE (CH) | 1993-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | HTR2A 4225/4885ESR1 3084/4885ADRA2A 4316/4885 |
| US-12540228-B2 | Cross linked surface coating and interfacial layer for a perovskite material photovoltaic device | HCN2, HCN1, BRSK1 | HTR2A 1228/4885ESR1 1630/4885ADRA2A 1793/4885 |
| US-12300485-B2 | Enhanced perovskite materials for photovoltaic devices | ZFX, KCNH1, CXXC4 | HTR2A 1794/4885ESR1 2776/4885ADRA2A 1416/4885 |
| US-12486235-B2 | Metal oxide nanoparticle with alkylsiloxane ligands bonded thereto | MACO1, CD4, ITGAV | HTR2A 3513/4885ESR1 780/4885ADRA2A 2554/4885 |
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | HTR2A 551/4885ESR1 4234/4885ADRA2A 1121/4885 |
| US-12243740-B2 | Enhanced perovskite materials for photovoltaic devices | ZFX, ZYX, CXXC5 | HTR2A 1341/4885ESR1 2323/4885ADRA2A 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.